Palladio seeks to position Orphan kidney therapy as safer alternative with $20 million series B

Palladio will use its $20 million series B round to determine for investors and potential partners where exactly its autosomal dominant polycystic kidney disease (ADPKD) therapy lixivaptan will fit on the market.

The round was led by new investor Samsara BioCapital with participation from Roche Venture Fund and existing investors Medicxi and Osage University Partners. ...